The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Managing Myositis in 3 Different Scenarios

Managing Myositis in 3 Different Scenarios

February 18, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Tashatuvango / shutterstock.com

Tashatuvango / shutterstock.com

SAN DIEGO—In Hot Topics in Myositis, a session held Nov. 7 at the 2017 ACR/ARHP Annual Meeting, rheumatologists discussed treating myositis patients in three different clinical scenarios: persistently elevated creatine kinase (CK), immune-mediated necrotizing myopathies and lung disease.

You Might Also Like
  • Myositis AutoantibodiesTriggered by Statins
  • Tips for Myositis Management
  • Myositis Autoantibodies as Biomarkers
Explore This Issue
February 2018
Also By This Author
  • 2 Markers May Help Predict Who will Progress to Sjögren’s

Elevated CK

Patients with persistently elevated levels of CK enzyme and normal muscle strength “may still have minimal, nonspecific muscle symptoms, like a cramp or spasm that doesn’t interfere with their day-to-day life,” said Rohit Aggarwal, MD, MS, associate pro­fessor of medicine at the University of Pittsburgh Medical Center.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How do you proceed with these asymptomatic hyper­CKemia patients? First, confirm whether a patient’s CK levels are truly elevated, he said. Thresholds for the upper limit of normal CK differ by race or ethnicity, and sex.1 Normal CK for African-American men is below 1,000, while normal for Caucasian men is below 200. CK levels are lower in women overall, but higher for African-American women than in Hispanic, Asian or Caucasian women. CK also decreases gradually with age.

Physical activity, particularly if it is unusual, “can have a transient CK increase up to 10–30 times the upper limit of normal,” said Dr. Aggarwal. “If you never exercise and go to the gym for an hour, your CK level can be really high.” After seven days of rest, about 70% of patients will have normal CK levels again, he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Based on the asymptomatic hyperCKemia guidelines, use a 97.5% cutoff for normal CK based on a patient’s race and sex, retest after seven days of rest, and look for 1.5 times the upper limit of normal to cut down on false positives.2 If a patient’s high CK levels are confirmed, look for non-neuromuscular causes that are easier to detect and treat, such as hypo- or hyperthyroidism, cardiovascular disease, pregnancy, celiac disease and medications. Statins are widely used and may raise CK levels from two to 10 times the upper limit of normal, he said.

“A common question is, ‘Do I need to stop the statin in someone with asymptomatic hyperCKemia? The answer is no. Can I start a statin if someone has asymptomatic hyperCKemia? The answer is absolutely yes,” he said. Check baseline CK before starting the patient on a statin. If they have no muscle symptoms, nothing more needs to be done. “If the patient does develop muscle symptoms, recheck the CK levels. If still normal and the patient has normal muscle strength, ask the patient if these symptoms are intolerable or if they affect day to day life. If not, continue the statin and follow up normally.” Patients with CK levels higher than five times the upper limit normal should stop their statin. Patients whose symptoms interfere with their daily life should also stop their statin, he said. After stopping the statin, muscle symptoms resolve in most cases.

Pages: 1 2 3 4 | Single Page

Filed Under: Meeting Reports, Soft Tissue Pain Tagged With: ACR/ARHP Annual Meeting, creatine, Interstitial Lung Disease, myositis, necrotizing myopathyIssue: February 2018

You Might Also Like:
  • Myositis AutoantibodiesTriggered by Statins
  • Tips for Myositis Management
  • Myositis Autoantibodies as Biomarkers
  • Statins Linked to Idiopathic Inflammatory Myositis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.